Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE

PR Newswire - Mon Sep 12, 2022

DUBLIN, Sept. 12, 2022 /PRNewswire/ -- Perrigo Company plc ( NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) on November 18, 2022, to review the Company's application for Opill^® daily oral contraceptive for OTC use.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

investor newsletter

A change in market leadership may be imminent. Plus, an index-beating U.S. dividend portfolio strategy

Tensions rise in Silicon Valley over sales of startup stocks

inside the market

How pro money managers are balancing exposure to Canadian and U.S. stocks

At the open: North American stock markets rise as rate-cut hopes linger

The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada

The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings

international business

Trump awarded 36 million more Trump Media shares worth $1.8-billion after hitting price benchmarks

The close: Stocks mixed as Fed leaves investors guessing as to when rate cuts will arrive